Last reviewed · How we verify
TAS-102, Regorafenib , Fruquintinib
TAS-102, Regorafenib , Fruquintinib is a Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. It is currently in Phase 3 development for Metastatic colorectal cancer, Gastrointestinal stromal tumor, Colorectal cancer.
TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2).
TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). Used for Metastatic colorectal cancer, Gastrointestinal stromal tumor, Colorectal cancer.
At a glance
| Generic name | TAS-102, Regorafenib , Fruquintinib |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor |
| Target | Thymidylate synthase, VEGFR2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TAS-102 works by incorporating into DNA and causing DNA damage, which triggers cell death in cancer cells. Regorafenib targets multiple kinases involved in tumor growth and angiogenesis, leading to reduced tumor size and progression. Fruquintinib selectively inhibits VEGFR2, which is crucial for tumor angiogenesis and growth.
Approved indications
- Metastatic colorectal cancer
- Gastrointestinal stromal tumor
- Colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Hypertension
- Hand-foot syndrome
- Rash
Key clinical trials
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
- JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan (PHASE3)
- Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. (PHASE2)
- Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan (PHASE3)
- A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (PHASE1)
- TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAS-102, Regorafenib , Fruquintinib CI brief — competitive landscape report
- TAS-102, Regorafenib , Fruquintinib updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about TAS-102, Regorafenib , Fruquintinib
What is TAS-102, Regorafenib , Fruquintinib?
How does TAS-102, Regorafenib , Fruquintinib work?
What is TAS-102, Regorafenib , Fruquintinib used for?
Who makes TAS-102, Regorafenib , Fruquintinib?
What drug class is TAS-102, Regorafenib , Fruquintinib in?
What development phase is TAS-102, Regorafenib , Fruquintinib in?
What are the side effects of TAS-102, Regorafenib , Fruquintinib?
What does TAS-102, Regorafenib , Fruquintinib target?
Related
- Drug class: All Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor drugs
- Target: All drugs targeting Thymidylate synthase, VEGFR2
- Manufacturer: Suzhou Suncadia Biopharmaceuticals Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Gastrointestinal stromal tumor
- Indication: Drugs for Colorectal cancer
- Compare: TAS-102, Regorafenib , Fruquintinib vs similar drugs
- Pricing: TAS-102, Regorafenib , Fruquintinib cost, discount & access